Simon, L., Zini, A., Dyachenko, A., Ciampi, A
Food and Drug Administration approved tirzepatide weekly injections for chronic weight management in adults who are overweight or have obesity, with at least one weight-related condition (such as high blood pressure, type 2 diabetes or high cholesterol), in addition to a reduced calorie diet and increased physical activity in November 2023
2004, 113: e472-e486
Low levels of vitamin B12 (vitamin B12 deficiency)
Similar reconstitution principles apply across peptides, as covered in our guides for semaglutide reconstitution and tirzepatide reconstitution
Unused pens may be kept at room temperature between 46F to 86F (8C to 30C) for up to 28 days before use